Author(s): Zhou J; Wearn A; Huck J; Hughes CS; Baracchini G; Sylvain E; Tremblay-Mercier J; Poirier J; Breitner JCSCS; Villeneuve S; Chakravarty MM; Tardif CL; Gauthier CJ; Daugherty AM; Turner GR; Spreng RN;

Background: Elevated brain iron deposition is recognized as a characteristic of normal aging and neurodegenerative diseases, particularly Alzheimer's disease (AD), where it correlated with amyloid-ß plaques and neurofibrillary tangles. Our study aimed to investigate the relationship between l ...

Article GUID: 41499788

Author(s): Cunningham NP; Tremblay-Mercier J; Baril AA; Dang-Vu TT; Lim A; Geddes MR; Badawy M; Poirier J; Ducharme S; Villeneuve S;

Background: Poor sleep is a modifiable factor associated with the development and progression of Alzheimer's Disease (AD). Pharmacological treatments and Cognitive Behavioural Therapy for Insomnia (CBT-I) which promote sleep have the potential to improve AD risk profile. In addition, prior re ...

Article GUID: 41450269

Author(s): Potvin-Jutras Z; Tremblay PL; Mohammadi H; Villeneuve S; Spreng RN; Gauthier CJ;

The apolipoprotein E4 (APOE4) allele is the strongest genetic risk factor for Alzheimer's disease (AD) and is linked to poorer cerebrovascular health. Cerebrovascular reactivity (CVR), an indicator of vascular reserve, and cerebral pulsatility (CP), a marker of vascular stiffness, are sensitive biomarkers of early vascular dysfunction associated with ...

Article GUID: 41353310

Author(s): Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Stri ...

The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now be ...

Article GUID: 41020412

Author(s): Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda- ...

The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years,SD 3.1]. Multimodal ...

Article GUID: 40778177

Author(s): Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM;

White matter hyperintensities (WMHs) are neuroimaging markers widely interpreted as caused by cerebral small vessel disease, yet emerging evidence suggests that a subset may have a neurodegenerative etiology. Current imaging methods have lacked the specificity to disentangle biological processes ...

Article GUID: 40585093

Author(s): Sanami S; Intzandt B; Huck J; Villeneuve S; Iturria-Medina Y; Gauthier CJ; Prevent-Ad Research Group None;

Alzheimer's disease (AD) is a complex disease that involves complex interactions between protein biomarkers such as amyloid beta (Aß) and tau, neurodegeneration, cerebrovascular health and inflammation. However, how these factors interact, especially in the early phases of disease development ...

Article GUID: 40347524

Author(s): Tremblay SA; Nathan Spreng R; Wearn A; Alasmar Z; Pirhadi A; Tardif CL; Chakravarty MM; Villeneuve S; Leppert IR; Carbonell F; Medina YI; Steele CJ; Gauthier CJ;

Early detection of pathological changes in Alzheimer's disease (AD) has garnered significant attention in the last few decades as interventions aiming to prevent progression will likely be most effective when initiated early. White matter (WM) alterations are among the earliest changes in AD, ...

Article GUID: 40086421

Author(s): Tremblay SA; Spreng RN; Wearn A; Alasmar Z; Pirhadi A; Tardif CL; Chakravarty MM; Villeneuve S; Leppert IR; Carbonell F; Medina YI; Steele CJ; Gauthier CJ;

Background: Alzheimer's disease (AD) is thought to result from a complex cascade of events involving several pathological processes. Recent studies have reported alterations in white matter (WM) microstructure in the early phase of AD, but WM remains understudied. We used a multivariate appro ...

Article GUID: 39782998

Author(s): Tremblay SA; Spreng RN; Wearn A; Alasmar Z; Pirhadi A; Tardif CL; Chakravarty MM; Villeneuve S; Leppert IR; Carbonell F; Medina YI; Steele CJ; Gauthier CJ;

Background: Alzheimer's disease (AD) is thought to result from a complex cascade of events involving several pathological processes. Recent studies have reported alterations in white matter (WM) microstructure in the early phase of AD, but WM remains understudied. We used a multivariate appro ...

Article GUID: 39785351

Author(s): Wearn A; Tremblay SA; Tardif CL; Leppert IR; Gauthier CJ; Baracchini G; Hughes C; Hewan P; Tremblay-Mercier J; Rosa-Neto P; Poirier J; Villeneuve S; Schmitz TW; Turner GR; Spreng RN;

The neuromodulatory subcortical nuclei within the isodendritic core (IdC) are the earliest sites of tauopathy in Alzheimer's disease (AD). They project broadly throughout the brain's white matter. We investigated the relationship between IdC microstructure and whole-brain white matter mic ...

Article GUID: 38830849